Stockholm, Sweden, October 11, 2024 – Pursuant to the instruction regarding the appointment of the Nomination Committee BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) shall have a Nomination Committee comprising one representative for each of the three principal shareholders in terms of votes, based on the information received from Euroclear Sweden AB on the last banking day in September 2024, as well as the Chairman of the Board (convener).
September 30, 2024, the three largest shareholders were Demban AB, Ackelsta AB and The Fourth Swedish National Fund (Fjärde AP-fonden).
The three owners who have agreed to be part of the Nomination Committee, Demban AB, Ackelsta AB and Fjärde AP-fonden, represent approx. 61 percent of the shares and approx. 84 percent of the votes in the company.
The nomination committee comprises the following members:
- Margareta Öhrvall, appointed by Demban AB
- Claes Andersson, appointed by Ackelsta AB
- Jannis Kitsakis, chairperson of the Nomination Committee appointed by Fjärde AP-fonden
The Nomination Committee shall prepare proposals for the 2025 Annual General Meeting regarding the Chairman of the Meeting, number of Board members, fees to be paid to the Chairman of the Board and Board members, election of Board members and Board Chairman, remuneration to the auditor and election of auditor and, if necessary, proposal for changes in the instruction to the Nomination Committee. The Nomination Committee’s proposals will be presented in the notice to the Annual General Meeting 2025, as well as on the company’s website, www.bioarctic.com
Shareholders wishing to submit a proposal to BioArctic’s Nomination Committee can do so by e-mail to: ir@bioarctic.se (label e-mails with ”Nomination Committee”) or by post addressed to:
BioArctic AB, Att: Nomination Committee, Warfvinges väg 35, SE-112 51 Stockholm, Sweden, not later than January 13, 2025.
The Annual General Meeting 2025 in BioArctic will be held on Thursday, May 22, 2025, at 16:30 p.m. (CET) in Stockholm. A request to have a matter dealt with at the meeting must be received by March 7, 2025, to be included in the notice.
—
For more information, please contact:
Oskar Bosson, Vice President Communications and Investor Relations
Telephone: + 46 70 410 71 80
E-mail: oskar.bosson@bioarctic.com
About BioArctic
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world’s first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer’s disease. Leqembi has been developed together with BioArctic’s partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson’s disease and ALS as well as additional projects against Alzheimer’s disease. Several of the projects utilize the company’s proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic’s B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.
The information was released for public disclosure, through the agency of the contact person above, at 08:30 a.m. CET on October 11, 2024.